Peter Brossart
Overview
Explore the profile of Peter Brossart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
273
Citations
5180
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eigentler T, Thomas I, Samoylenko I, Erdmann M, Heinzerling L, Ochsenreither S, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39904560
Background: CV8102, a toll-like receptor 7/8 and RIG I agonist, has demonstrated antitumor immune responses in preclinical studies. We investigated intratumoral (IT) administration of CV8102 in patients with anti-programmed cell...
2.
Zeyen T, Weller J, Schneider M, Potthoff A, Schaub C, Roever L, et al.
Neurooncol Adv
. 2025 Feb;
7(1):vdaf005.
PMID: 39902392
Background: Polychemotherapy based on high-dose methotrexate (HD-MTX) is the standard therapy for newly diagnosed younger patients (<65 years) with primary CNS lymphoma (PCNSL). In the modified Bonn protocol, consolidation therapy...
3.
Arndt V, Doege D, Frohling S, Albers P, Algul H, Bargou R, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):39.
PMID: 39825921
No abstract available.
4.
Baertsch M, Schlenzka J, Hielscher T, Raab M, Sauer S, Merz M, et al.
Blood
. 2025 Jan;
PMID: 39808798
The multicenter, phase III GMMG ReLApsE trial (EudraCT-No:2009-013856-61) randomized relapsed and/or refractory multiple myeloma (RRMM) patients equally to lenalidomide/dexamethasone (LEN/DEX, 25mg days 1-21/40mg weekly, 4-week cycles) re-induction, salvage high dose...
5.
Saal J, Eckstein M, Ritter M, Brossart P, Luetkens J, Ellinger J, et al.
JAMA Oncol
. 2024 Dec;
11(2):154-161.
PMID: 39724246
Importance: Progressive disease (PD) in patients treated with immune checkpoint inhibitors (ICIs) varies widely in outcomes according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Efforts to...
6.
Saal J, Eckstein M, Ritter M, Brossart P, Holzel M, Grunwald V, et al.
Eur J Cancer
. 2024 Dec;
215:115163.
PMID: 39662097
Background: Treatment beyond progression (TBP) is common in patients treated with immune-checkpoint inhibitors (ICI), however, there is no biomarker to select patients that are more likely to derive benefit from...
7.
Mai E, Nogai A, Lokhorst H, van der Holt B, Zweegman S, Weisel K, et al.
Hemasphere
. 2024 Nov;
8(11):e70052.
PMID: 39569355
No abstract available.
8.
Schlaweck S, Radcke A, Kampmann S, Becker B, Brossart P, Heine A
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518156
Background: FMS-like tyrosine kinase 3 (FLT3) mutations or internal tandem duplication occur in 30% of acute myeloid leukemia (AML) cases. In these cases, FLT3 inhibitors (FLT3i) are approved for induction...
9.
Holderried T, Stasik I, Schmitz M, Schmitz F, Meyer T, Stauss L, et al.
Front Digit Health
. 2024 Nov;
6:1414442.
PMID: 39498102
Background: The use of online information and communication is globally increasing in the healthcare sector. In addition to known benefits in other medical fields, possible specific potentials of eHealth lie...
10.
Praktiknjo M, Pena Solano A, Sadeghlar F, Welchowski T, Schmid M, Mohring C, et al.
Sci Rep
. 2024 Sep;
14(1):22146.
PMID: 39333610
Lenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with...